Psiconáutica Editorial Team · 13 November 2026
At a glance
- The US DEA proposes 2027 manufacturing quotas of 33,296 g of MDMA and 12,002 g of ibogaine, which the notice says are above the revised quotas it had proposed for 2026.
- Among Schedule I substances, the agency explicitly justifies only these two increases, citing increased research and clinical trials in post-traumatic stress and depression, and says they align with two executive orders.
- The proposal is open for comment until 10 December 2026. It does not change the scheduling of any substance or authorize its use.
Each year the US Drug Enforcement Administration (DEA) sets how much of each Schedule I and II substance may be legally manufactured in the country. The 2027 proposal was published in the Federal Register on 10 November 2026 and signed on 3 November by DEA Administrator Terrance C. Cole. In it, the agency explicitly raises the ceilings for two substances being studied in clinical trials: MDMA and ibogaine.
What it proposes
These are the proposed 2027 quotas, in grams, for a selection of psychedelic substances in the table. The figure in brackets, given for reference, comes from the final 2026 quota notice published on 5 January:
- MDMA: 33,296 (12,000 in January 2026).
- Ibogaine: 12,002 (210).
- Psilocybin: 60,000 (50,000); psilocyn: 93,600 (80,000).
- Methylone: 42,500 (30,000).
- DMT (25,000), 5-MeO-DMT (30,000), MDA (12,000), LSD (1,200) and mescaline (1,200): the same figures as in January 2026.
The table also includes other substances of interest, such as 2C-B (5,100 g) and DOM (25 g), which we do not compare with 2026. The comparison with January does not amount to an increase over current quotas. The 2027 notice compares its figures with “2026 proposed revised” quotas that it does not identify and that we have not been able to locate. For that reason, we do not claim that psilocybin, psilocyn or methylone rise above their current levels. Noribogaine does not appear in the table, and the notice covers other Schedule I and II substances that this article does not analyze.
Why, according to the DEA
The document says it proposes quotas above the proposed revised 2026 levels for two Schedule I substances, MDMA and ibogaine. The aim is to support manufacturing linked to increased research and clinical trials on potential treatments for conditions such as post-traumatic stress disorder and depression. The DEA says this increase aligns with two executive orders. Order 14379, of 29 January 2026, addresses addiction and recovery. Order 14401, of 18 April 2026, requires, according to the text, a pathway for eligible patients to access psychedelic drugs, including ibogaine compounds, under the federal Right to Try Act.
What it does not mean
An aggregate quota is a ceiling for DEA-registered manufacturers, not a forecast of output or a permission to use. These substances remain in federal Schedule I, and the proposal does not change their scheduling. Nor does it say anything about their efficacy or safety.
Limitations
We read the official text on govinfo and the final 2026 quota notice. We could not locate the document with the proposed revised 2026 quotas that the notice refers to, so the comparison is limited to the January figures. The 2027 figures may change after the comment period.
What it means
The proposal is an administrative indicator of growing clinical research with MDMA and ibogaine in the US, not evidence that they work. To follow the wider regulatory picture, see our article on the DEA proposal to place five tryptamines in Schedule I and our guide to psychedelic science and therapy.
Sources
- DEA. “Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2027.” 91 FR 72566, 10 November 2026, document 2026-22843, docket DEA-1730P (govinfo).
- DEA. “Established Aggregate Production Quotas … for 2026.” 91 FR 287, 5 January 2026, document 2025-24277 (govinfo).
Image
Illustrative image of the Robert F. Kennedy Department of Justice Building in Washington, D.C.; the DEA is part of the Department of Justice. This is not DEA headquarters. Photo: Tony Webster, via Wikimedia Commons. License CC BY 2.0.
Educational content written from a harm-reduction perspective and with respect for individual freedom. It does not replace information from a healthcare professional and does not aim to encourage or condemn any drug use.
